Back to Search
Start Over
MMP3 is a reliable marker for disease activity, radiological monitoring, disease outcome predictability, and therapeutic response in rheumatoid arthritis
- Source :
- Best Practice & Research Clinical Rheumatology. 32:550-562
- Publication Year :
- 2018
- Publisher :
- Elsevier BV, 2018.
-
Abstract
- Matrix metalloproteinase-3 or MMP3 also known as stromelysin-1 is an enzyme that is actively involved in joint destruction in rheumatoid arthritis (RA) patients. Screening the last three decades, it appears that serum levels of MMP3 reflect positively RA disease activity, joint and bone injury, and radiological erosion and predict disease outcome and drug responsiveness as summarized in several publications reporting outcomes on more than 8000 patients with RA. MMP-3 monitoring should be embedded in the routine assessment and accompany therapeutic modalities, in personalized medical RA management.
- Subjects :
- Male
0301 basic medicine
MMP3
medicine.medical_specialty
Disease outcome
Arthritis, Rheumatoid
Disease activity
03 medical and health sciences
0302 clinical medicine
Rheumatology
Internal medicine
medicine
Humans
030203 arthritis & rheumatology
Joint destruction
business.industry
Bone Injury
Middle Aged
medicine.disease
Therapeutic modalities
Treatment Outcome
030104 developmental biology
Rheumatoid arthritis
Radiological weapon
Female
Matrix Metalloproteinase 3
business
Biomarkers
Subjects
Details
- ISSN :
- 15216942
- Volume :
- 32
- Database :
- OpenAIRE
- Journal :
- Best Practice & Research Clinical Rheumatology
- Accession number :
- edsair.doi.dedup.....6debab8b6fa399aed9eacc48ae0b43c2